LENSAR Q1 Earnings Call Highlights

LENSAR NASDAQ: LNSR executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said first-quarter results reflected that period of uncertainty, but highlighted continued growth in recurring revenue and rising procedure volumes.

MarketBeat • May 8, 2026

LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

LENSAR® Reports First Quarter 2026 Results and Provides Business Update

7 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026

GlobeNewsWire • May 8, 2026

LENSAR® to Report First Quarter 2026 Results on May 8, 2026

ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026.

GlobeNewsWire • Apr 30, 2026

LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 31, 2026

LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

15 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025

GlobeNewsWire • Mar 31, 2026

LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review

In March 2025, Alcon agreed to acquire the laser solutions company for $14.00 per share for an aggregate implied value of approximately $356 million.

Benzinga • Mar 17, 2026

LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC (“Alcon”) to terminate the merger agreement between the parties.

GlobeNewsWire • Mar 16, 2026

LENSAR® Provides Update on Pending Acquisition by Alcon

ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today provided an update on the status of its pending acquisition by Alcon Research, LLC (“Alcon”).

GlobeNewsWire • Feb 25, 2026

LENSAR® Reports Third Quarter 2025 Results and Provides Business Update

18 ALLY Robotic Cataract Laser Systems ® (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser installed base grew 20% over 3Q 2024 ORLANDO, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2025 and provided an update on key operational initiatives.

GlobeNewsWire • Nov 6, 2025